COM-2025-055 PLEASE Drug Information Please Please Please PharmPix Clinical Department

Drug Information:

Remember that medical literature is dynamic and is continuously scientific changing knowledge is developed. exhort the frequent revision of treatment guidelines to assure that recommendations consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding document, you can call us directly or view PharmPix communications online.

QUESTIONS

Call us at 787-522-5252-ext.219

Access our recent communications providers' https://www.pharmpix.com/providers/



PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest upto-date drug information requested.

FDA Approves Prefilled Shingrix Vaccine

The FDA has approved a new prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine, RZV), offering a more convenient option for preventing shingles in adults. Manufactured by GSK, this updated version contains both the lyophilized antigen and liquid adjuvant in a single syringe, eliminating the need for reconstitution and simplifying the vaccination process for healthcare professionals. The approval of the new presentation is based on data demonstrating technical comparability between the new and existing vaccine presentations.

Shingrix is indicated for adults aged 50 years and older, as well as adults 18 years and older who are or will be immunocompromised due to disease or therapy. The Centers for Disease Control and Prevention (CDC) recommends two doses of Shingrix for these groups, administered 2 to 6 months apart.

Each year, shingles affects approximately 1 million people in the United States. While most people experience shingles only once, it can recur and lead to complications, the most common being postherpetic neuralgia (PHN), a persistent and sometimes debilitating nerve pain.

Access to Shingrix is widely available. Currently, 96% of private insurance plans and Medicare Part D fully cover the vaccine, leaving most patients with no out-of-pocket cost.

As for safety, common side effects reported in adults aged 50 and older include local reactions at the injection site, as well as general symptoms like muscle pain and fatigue. Additionally, an increased risk of Guillain-Barré syndrome was identified within 42 days following vaccination. Shingrix is not recommended for individuals with a history of severe allergic reactions to any of its components.



If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

PharmPix Drug Information Communication Number COM-2025-055 August 2025



REFERENCES:

- 1. CDC. (2024, October 22). Shingles vaccine recommendations. Shingles (Herpes Zoster). https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html
- Lutton, L. (2025, July 17). FDA approves prefilled vaccine presentation for Shingrix. Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/fda-approves-prefilled-vaccine-presentation-for-shingrix
- 3. US FDA approves GSK's Shingrix in a prefilled syringe presentation. (2025, July 17). Gsk.com. https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-shingrix-in-a-prefilled-syringe-presentation/
- 4. (N.d.). Gskpro.com. Retrieved August 6, 2025, from https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF



